RCS - Creo Medical Group - KOL presentations on Creo Core Products at DDW

Creo MedicalAnnouncement

30/04/2026 07:02

For best results when printing this announcement, please click on link below:
https://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20260430:nRSd4820Ca&default-theme=true

RNS Number : 4820C  Creo Medical Group PLC  30 April 2026

 

Creo Medical Group plc

("Creo", the "Company" or the "Group")

 

KOL presentations on Creo Core Products at DDW

Data presentations at Digestive Disease Week further validate Creo Medical's
endoscopic devices

 

Creo Medical Group plc (AIM: CREO), the medical device company focused on the
emerging field of minimally invasive surgical endoscopy for pre-cancer and
cancer patients, announces that it will be attending the Digestive Disease
Week ("DDW") 2026 conference in Chicago, IL, taking place between 2-5 May 2026
(booth 4536).

 

The conference will feature a range of presentations from Key Opinion Leaders
("KOLs") showcasing minimally invasive endoscopy procedures, with certain KOLs
presenting studies further validating Creo Medical's endoscopic devices.
Presentations include:

 

Zacharias P. Tsiamoulos, Director of Endoscopic Microsurgery Department at
Hygeia Hospital, will present data as part of the ASGE World Cup displaying
that sequential intermuscular and full thickness dissection with
bipolar/microwave-assisted endoscopic submucosal dissection ("ESD") resulted
in R0 resection and no postoperative complications. This study is significant
in further validating Creo Medical's CROMA Advanced Energy Platform, powered
by Kamaptive, which combines advanced bipolar radiofrequency and microwave
energy to deliver safe and precise controlled coagulation.

 

Theodoros Alexopoulos, East Kent Hospitals University NHS Foundation Trust,
will present prospective data from over 600 Speedboat™ assisted ESD cases
for colorectal cancer, challenging the established 1mm cancer-free vertical
margin threshold.

 

Eduardo Albéniz, Gastroenterology Specialist at Complejo Hospitalario de
Navarra, will also be presenting an early experience study of bipolar knife
peroral endoscopic myotomy ("POEM") using Speedboat™ and the CROMA Advanced
Energy Platform. The study showed 100% technical success across 75 patients
and demonstrates the potential benefits of POEM procedures with Speedboat and
reduced instrument exchanges.

 

For more information about the event, please see the DDW website here
(https://ddw.org/) .

 

For further information please contact:

 

 Creo Medical Group plc                                                         www.creomedical.com
                                                                                (https://protect.checkpoint.com/v2/___http:/www.creomedical.com/___.YzJ1OmludHVpdGl2ZTpjOm86NWJlYzBmMzJjY2MyZTBiZWFkNmJkZmVmNzdhM2MwMTI6NjoyYWU4OjczNzQyNWUwODBjYTEwNzAxYWMzNWEyZDQ3YzI1ZmEwYWMzYTc4M2Q2M2NjYzEyNTQwZWM3ODc4NTk3NTE4YTQ6cDpUOk4)
 Richard Craven, Company Secretary                                              Via Walbrook PR

 Deutsche Numis (Nominated Adviser, Joint Broker and Financial Adviser)         +44 (0)20 7260 1000

 Duncan Monteith / Sher Shah

 Shore Capital (Joint Broker)                                                   +44 (0)20 7408 4090

 Daniel Bush / Lucy Bowden

 Walbrook PR Ltd                       Tel: +44 (0)20 7933 8780 or creo@walbrookpr.com (mailto:creo@walbrookpr.com)
 Paul McManus / Alice Woodings         Mob: +44 (0)7980 541 893 / +44 (0)7407 804 654

 

 

 

About Creo Medical

Creo is a medical device company focused on the development and
commercialisation of minimally invasive electrosurgical devices, bringing
advanced energy to endoscopy.

 

The Company's vision is to improve patient outcomes through the development
and commercialisation of a suite of electrosurgical medical devices, each
enabled by CROMA, powered by Kamaptive. The Group has developed the CROMA
powered by Kamaptive full-spectrum adaptive technology to optimise surgical
capability and patient outcomes. Kamaptive is a seamless, intuitive
integration of multi-modal energy sources, optimised to dynamically adapt to
patient tissue during procedures such as resection, dissection, coagulation,
and ablation of tissue. Kamaptive technology provides clinicians with
increased flexibility, precision and controlled surgical solutions. CROMA
currently delivers bipolar radiofrequency ("RF") energy for precise localised
cutting and focused high frequency microwave ("MW") energy for controlled
coagulation and ablation via a single accessory port. This technology,
combined with the Group's range of patented electrosurgical devices, is
designed to provide clinicians with flexible, accurate and controlled clinical
solutions. The Directors believe the Company's technology can impact the
landscape of surgery and endoscopy by providing a safer, less invasive and
more cost-efficient option for procedures.

 

For more information, please refer to the website www.creomedical.com
(https://protect.checkpoint.com/v2/___http:/www.creomedical.com/___.YzJ1OmludHVpdGl2ZTpjOm86NWJlYzBmMzJjY2MyZTBiZWFkNmJkZmVmNzdhM2MwMTI6NjoyYWU4OjczNzQyNWUwODBjYTEwNzAxYWMzNWEyZDQ3YzI1ZmEwYWMzYTc4M2Q2M2NjYzEyNTQwZWM3ODc4NTk3NTE4YTQ6cDpUOk4)

 

 

 

This information is provided by Reach, the non-regulatory press release distribution service of RNS, part of the London Stock Exchange. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  NRAFFFFISFIAFIR



            Copyright 2019 Regulatory News Service, all rights reserved